GenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%
- Written by PR Newswire
R&D Innovation to Lead the Future, Deepening Customer Value Creation
- Sustained High Revenue Growth: GenScript Group's five-year CAGR stands at an impressive 30%, with a strong global operation and stable cash flow. In 2023, the group's best-in-class cell therapy product CARVYKTI®, achieved sales exceeding $500 million, becoming the...
